| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/08/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/08/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/31/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/31/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/31/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/31/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/23/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/22/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/18/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 05/18/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/18/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/17/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/15/2023 |
4
| Freiman Paul E. (Director) has filed a Form 4 on NovaBay Pharmaceuticals, Inc.|
Txns:
| Exercised 858 restricted stock units
@ $0 |
|
| 05/15/2023 |
4
| Zheng Yenyou (Director) has filed a Form 4 on NovaBay Pharmaceuticals, Inc.|
Txns:
| Exercised 858 restricted stock units
@ $0 |
|
| 05/15/2023 |
4
| WU MIJIA (Director) has filed a Form 4 on NovaBay Pharmaceuticals, Inc.|
Txns:
| Exercised 858 restricted stock units
@ $0 |
|
| 05/15/2023 |
4
| Sit Swan (Director) has filed a Form 4 on NovaBay Pharmaceuticals, Inc.|
Txns:
| Exercised 858 restricted stock units
@ $0 |
|
| 05/15/2023 |
4
| Garlikov Julie (Director) has filed a Form 4 on NovaBay Pharmaceuticals, Inc.|
Txns:
| Exercised 858 restricted stock units
@ $0 |
|
| 05/15/2023 |
4
| Zheng Yongxiang (Director) has filed a Form 4 on NovaBay Pharmaceuticals, Inc.|
Txns:
| Exercised 858 restricted stock units
@ $0 |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/31/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/31/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/24/2023 |
3
| Law Tommy (Interim CFO) has filed a Form 3 on NovaBay Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in NOVABAY PHARMACEUTICALS, INC. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|